GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » FCF Yield %

INTS (Intensity Therapeutics) FCF Yield % : -43.28 (As of Dec. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Intensity Therapeutics's Trailing 12-Month Free Cash Flow is $-13.50 Mil, and Market Cap is $31.12 Mil. Therefore, Intensity Therapeutics's FCF Yield % for today is -43.28%.

The historical rank and industry rank for Intensity Therapeutics's FCF Yield % or its related term are showing as below:

INTS' s FCF Yield % Range Over the Past 10 Years
Min: -44.66   Med: 0   Max: 0
Current: -43.28


INTS's FCF Yield % is ranked worse than
72.86% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs INTS: -43.28

Intensity Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Intensity Therapeutics FCF Yield % Historical Data

The historical data trend for Intensity Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics FCF Yield % Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - - - -6.13

Intensity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.62 -3.22 -24.49 -25.09 -30.00

Competitive Comparison of Intensity Therapeutics's FCF Yield %

For the Biotechnology subindustry, Intensity Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intensity Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's FCF Yield % falls into.



Intensity Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Intensity Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-7.205 / 117.489558
=-6.13%

Intensity Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.972 * 4 / 52.960098
=-30.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intensity Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Intensity Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intensity Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
Executives
Emer Leahy director 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers officer: Executive VP of CF 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender director, 10 percent owner, officer: President and CEO 765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg director PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski officer: Interim CFO 61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880

Intensity Therapeutics Headlines

From GuruFocus